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Colorectal cancer screening and treatment are rapidly evolving.
Aims
To reappraise stool-based colorectal cancer screening in light of chang-
ing test performance characteristics, lower test cost and increasing colo-
rectal cancer care costs.
Methods
Using a Markov model, we compared faecal DNA testing every 3 years,
annual faecal occult blood testing or immunochemical testing, and col-
onoscopy every 10 years.
Results
In the base case, faecal occult blood testing and faecal immunochemical
testing gained life-years ⁄person and cost less than no screening. Faecal
DNA testing version 1.1 at $300 (the current PreGen Plus test) gained
5323 life-years ⁄100 000 persons at $16 900 ⁄ life-year gained and faecal
DNA testing version 2 (enhanced test) gained 5795 life-years ⁄100 000
persons at $15 700 ⁄ life-year gained vs. no screening. In the base case
and most sensitivity analyses, faecal occult blood testing and faecal
immunochemical testing were preferred to faecal DNA testing.
Faecal DNA testing version 2 cost $100 000 ⁄ life-year gained vs. faecal
immunochemical testing when per-cycle adherence with faecal
immunochemical testing was 22%. Faecal immunochemical testing with
excellent adherence was superior to colonoscopy every 10 years.
Conclusions
As novel biological therapies increase colorectal cancer treatment costs,
faecal occult blood testing and faecal immunochemical testing could
become cost-saving. The cost-effectiveness of faecal DNA testing com-
pared with no screening has improved, but faecal occult blood testing and
faecal immunochemical testing are preferred to faecal DNA testing when
patient adherence is high. Faecal immunochemical testing may be compa-
rable to colonoscopy every 10 years in persons adhering to yearly testing.
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INTRODUCTION
Colorectal cancer (CRC) affects up to 6% of the popu-
lation and is the second leading cause of cancer-
related death in the US.1 Each year, approximately
145 000 new cases are diagnosed and approximately
55 000 deaths are attributed to CRC in the US.2
Screening decreases CRC incidence and mortality and
is cost-effective,3–13 but only a minority of the popu-
lation has been screened.14, 15 Patient preferences for
invasive vs. non-invasive screening tests vary,16–18
and the availability of some tests may be limited.19
In 2004, we first explored the potential role of fae-
cal DNA testing (F-DNA) in average-risk persons.20 We
concluded that it could not be considered a substitute
for traditional screening methods, but that it could
have an important impact if it attracted persons who
are not currently screened for CRC.20 A prospective
trial of the original PreGen Plus faecal DNA test
(EXACT Sciences Corporation, Marlboro, MA, USA and
LabCorp, Burlington, NC, USA) subsequently found the
test to be superior to faecal occult blood testing (FOBT)
in detecting CRC and large adenomas,21 but its perfor-
mance was inferior to our original estimates and its
projected effectiveness and cost-effectiveness
declined.22
Colorectal cancer screening is a rapidly evolving
field and key variables that affect estimates of effec-
tiveness and cost-effectiveness are changing, including
test performance characteristics and cost, and costs of
CRC care. Technical advances in DNA stabilization,23
DNA extraction from stool,24 and use of gene-specific
methylation25 have improved the faecal DNA test.26
Test cost has decreased to approximately $300 after
write-offs (B. Berger, personal communication; EXACT
Sciences Corporation). At the same time, bevacizumab
(an antibody targeting vascular endothelial growth
factor, a known regulator of tumour cell angiogenesis)
and cetuximab (an antibody targeting the epidermal
growth factor receptor, a tyrosine kinase important in
the regulation of growth and survival pathways in
CRC cells)27–29 have emerged as novel treatments that
enhance the efficacy of chemotherapy for advanced
CRC,28, 30 but also markedly increase treatment costs.31
Our aims were to reappraise non-invasive stool-
based screening for colorectal neoplasia in persons
unwilling or unable to undergo invasive screening
with sigmoidoscopy or colonoscopy in light of chang-
ing faecal DNA test performance characteristics,21, 26
lower test cost and increasing costs of CRC care. We
compared F-DNA, guaiac-based FOBT and faecal
immunochemical testing (FIT). Because adherence to
yearly guaiac-based FOBT is poor,15, 32–44 we exam-
ined in detail the potential impact of imperfect adher-
ence on the effectiveness and cost-effectiveness of
screening strategies. We previously examined the
cost-effectiveness of other modalities, including
colonoscopy.11, 20, 22, 45 Although we focus here on
stool-based testing, we report results for screening
colonoscopy for purposes of comparison.
MATERIALS AND METHODS
Literature review and data sources
The sources for most model inputs have been
described previously.11, 20, 22, 45 For updated clinical
information on F-DNA and FIT, we searched PubMed
using the terms faecal DNA, colorectal cancer, faecal
immunohistochemistry, detection, sensitivity, specific-
ity and test performance, we reviewed national meet-
ing abstracts, and we obtained data from EXACT
Sciences Corporation and FDA submission data from
Enterix Inc. (Edison, NJ, USA), maker of InSure FIT.
For updated cost data, we searched PubMed using the
terms colorectal cancer, chemotherapy, and cost, we
reviewed national meeting abstracts, we obtained data
from EXACT Sciences Corporation, and we used 2006
Medicare fee schedules, as detailed below.46
Decision analytic model
Our decision analytic model and its calibration and
validation have been described in detail.11, 20, 22, 45, 47
The model is constructed in TreeAge (TreeAge Soft-
ware, Inc., Williamston, MA, USA) and the Natural
History model is calibrated to reproduce the natural
history and age-specific incidence and prevalence of
colorectal adenomas and CRC in the US without
screening.11, 20, 22, 45, 47 Screening strategies are then
superimposed on the Natural History model. As
described previously, the model’s predictions for con-
ventional strategies are consistent with available clini-
cal data.11, 20, 22, 45, 47 For the current analysis, the
model was modified to allow variable adherence rates
every time a screening test was offered. To validate
this modification, we have modelled a cohort repre-
senting the one studied by Mandel et al.32, 33 with
FOBT offered and followed up as in that study.22 Our
model predicts a 21% reduction in CRC incidence over
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18 years vs. 20% observed in the study,33 and a 36%
reduction in CRC mortality over 16 years vs. 33%
observed in the study.32
Natural history
The principal health states in the model are (Figure 1):
normal; small (<10 mm) adenomatous polyp; large
(‡10 mm) adenomatous polyp; localized, regional, or
distant CRC and dead. Approximately 85% of CRCs
develop through a polypoid adenoma. In the Natural
History model, CRCs are diagnosed with colonoscopy
once they lead to symptoms. Diagnosed CRCs are
treated, resulting in stage-specific sur-
vival.11, 20, 28, 30, 45, 48–51 Persons surviving CRC treat-
ment enter surveillance (see below). Beginning at age
50 years, average-risk persons progress through the
model for 50 1-year cycles, until age 100 years or
death. Age-specific non-CRC mortality rates reflect US
life table data.52 Model inputs are shown in Table 1.
Screening strategies and surveillance
We compared Natural History, F-DNA, annual guaiac-
based FOBT and annual FIT. First, a screening interval
for F-DNA was selected that could be considered cost-
effective compared to a shorter screening interval, as
described below.
Screening strategies were superimposed on the Nat-
ural History model. In the base case, in all strategies,
screening and surveillance with perfect adherence were
performed up to and including age 80. Variable adher-
ence was a principal focus of sensitivity analyses.
After age 80, colonoscopy was performed only to eval-
uate symptoms. With colonoscopy, polyps were
removed and CRCs were biopsied, if detected. If
F-DNA, FOBT or FIT were positive, colonoscopy
followed with polypectomy and biopsy as necessary. If
colonoscopy was normal after a positive non-invasive
test, the non-invasive test was assumed to be false
positive and screening resumed in 10 years with the
primary screening strategy. CRC was managed, and
symptomatic CRC could be detected, as in the Natural
History model.
In all strategies, after adenoma detection, patients
underwent surveillance colonoscopy every 5 years.53, 54
Persons developing CRC underwent colonoscopy at
diagnosis, 3 years later and then every 5 years
thereafter.53, 54
Faecal occult blood testing and faecal
immunochemical testing
In the FOBT strategy, annual testing3, 53, 55 was offered
with test performance characteristics as modelled pre-
viously (Table 1).22 FIT was evaluated with annual
testing and test performance characteristics based on
available literature56–66 and FDA submission data from
Enterix Inc., maker of InSure FIT.67 Reported FIT sen-
sitivities range from 30% to 100% for CRC and from
20% to 71% for large adenoma, with specificities of
86–99%.56–66 In the base case for FIT, we assumed
sensitivity of 76% for CRC, 40% for large adenoma











Sx, RxSx, RxSx, Rx
Large 
polyp
Figure 1. Markov states in the
natural history model. Persons
cycle between states every
year from age 50 to 100.
Screening strategies were
superimposed on the natural
history model.
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Table 1. Inputs in the cost-effectiveness model
Variable Base case value (range)* References
Clinical
Polyp prevalence at age 50 (%) 15 91–93
Small polyp (%) 95 93–95
Large polyp (%) 5 93–95
Annual transition rate to small polyp from normal (%) Age specific, 1.1–1.9 91–95
Annual transition rate to large polyp from small polyp (%) 1.5 93–96
Annual transition rate to cancer without polypoid
precursor (%)
Age specific, 0.006–0.086 9, 91–93, 97
Annual transition rate to cancer from large polyp (%) 5 9, 91–93, 97
Symptomatic presentation of localized cancer (%) 22 ⁄ year over 2 years 97
Symptomatic presentation of regional cancer (%) 40 ⁄ year over 2 years 97
Mortality rate from treated localized cancer (%) 1.74 ⁄ year in first 5 years 97
Mortality rate from treated regional cancer (%) 8.6 ⁄ year in first 5 years 97
Mean survival from distant cancer (year) 1.9 28, 30, 31, 48–51, 78, 79, 97
Mortality rate from cancer treatment (%) 2 9, 10
Faecal occult blood testing sensitivity for cancer (%) 40 (30–60) 9, 10
Faecal occult blood testing sensitivity for large polyp (%) 10 (5–15) 9, 10
Faecal occult blood testing specificity (%)§ 92 (90–97) 9, 10
FIT testing sensitivity for cancer (%) 76 (62–88) 56–66
FIT testing sensitivity for large polyp (%) 40 (20–67) 56–66
FIT testing specificity (%)§ 91 (86–98) 56–66
Faecal DNA version 1 testing sensitivity for cancer (%) 52 (35–68) 21
Faecal DNA version 1 testing sensitivity for large polyp (%) 18 (14–22) 21
Faecal DNA version 1 testing specificity (%)§ 94 (93–96) 21
Faecal DNA version 1.1 testing sensitivity for cancer (%) 73 (57–84) 26
Faecal DNA version 1.1 testing sensitivity for large polyp (%) 18 (14–22) 26
Faecal DNA version 1.1 testing specificity (%)§ 89 (83–94) 26
Faecal DNA version 2 testing sensitivity for cancer (%) 88 (74–95) 26
Faecal DNA version 2 testing sensitivity for large polyp (%) 18 (14–22) 26
Faecal DNA version 2 testing specificity (%)§ 82 (74–88) 26
Colonoscopy sensitivity for cancer (%) 95 (90–97) 9, 10
Colonoscopy sensitivity for large polyp (%) 90 (85–95) 9, 10
Colonoscopy sensitivity for small polyp (%) 85 (80–90) 9, 10
Colonoscopy major complication rate (%) 0.1 (0.05–0.5) 9, 10
Colonoscopy mortality rate (%) 0.01 (0.01–0.03) 9, 10
Cost ($)
Faecal occult blood testing 15 (15–56) 46
FIT testing 22 (22–95) 46
Faecal DNA testing 300 (300–495) **
Colonoscopy 920 (710–1350) 7, 9, 11, 20, 47, 98
Colonoscopy with lesion removal 1350 (990–2030) 7, 9, 11, 20, 47, 98
Endoscopy complication 29 000 (16 000–43 000) 71, 72
Colorectal cancer care by stage–
Localized 51 000 (40 000–62 000) 5, 73–75
Regional 98 000 (85 000–105 000) 5, 28, 30, 31, 48–51, 73–75, 78, 79
Distant 200 000 (175 000–230 000) 5, 28, 30, 31, 48–51, 73–75, 78, 79
* Range for test sensitivity and specificity used in Monte Carlo simulation.
 Derived from epidemiological and autopsy data.
 The annual mortality rate applies to those surviving to the beginning of each year, reflecting exponential decay as the fraction of
persons surviving decreases at a rate proportional to its value.
§ Sensitivity for small polyp set at (1 ) specificity).
– Derived from Centers for Medicare and Medicaid Services and published data.
** Derived from LabCorp list price and average reimbursement (B. Berger, personal communication; Exact Sciences Corp.).
FIT, faecal immunochemical testing.
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Faecal DNA testing
Faecal DNA testing version 1 was defined as the
strategy using the prototype test evaluated by Impe-
riale et al.21 This test had sensitivities of 52% for
CRC and 18% for large adenoma and specificity of
94%.21 F-DNA version 2 was defined as the strategy
using the test recently reported by Itzkowitz et al.26
This test represents the optimal marker combination
of vimentin methylation and a DNA integrity assay,
with sensitivity of 88% for CRC and specificity of
82%.26 The sensitivity of F-DNA version 2 for large
adenoma has not been reported formally. We assumed
that the sensitivity for large adenoma of F-DNA version
2 was 18%, the same as for version 1. For F-DNA
versions 1 and 2, we assumed that F-DNA could
not distinguish normal from small adenoma. Thus,
F-DNA was positive when the most advanced
lesion was a small adenoma at a rate defined as
(100% ) specificity).
The test currently available on the market is version
1.1 (PreGen Plus, LabCorp). Compared with version 1,
version 1.1 includes a DNA stabilization buffer and an
improved gel capture method for isolating DNA.18, 23–
25 When the version 1 test was enhanced in these
ways in the recent study by Itzkowitz et al., sensitivity
for CRC was 73% and specificity was 89%.26 We
assumed that the sensitivity for large adenoma of F-
DNA version 1.1 was 18%, the same as for the other
versions of the test.
Before evaluating F-DNA strategies, an appropriate
screening interval was selected. As described
previously,20 we examined F-DNA at progressively
shorter screening intervals ranging from 1 to 5
years. Screening at a given interval (e.g. 4 years)
was compared to screening at a longer interval (e.g.
5 years), yielding the incremental cost per life-year
gained when shortening the interval. For the base
case, we selected a screening interval consistent with
the commonly accepted ‘willingness to pay’ thresh-
old of $50 000 ⁄ life-year gained.68–70 Thus, in the
base case, F-DNA was offered every 3 years (see
Results).
Screening colonoscopy
The screening colonoscopy strategy included colonos-
copy every 10 years (COLO), if no adenomas were
detected. Polyps were removed upon detection and
masses underwent biopsy. Test performance character-
istics and costs are presented in Table 1. After detec-
tion of adenomas, surveillance was performed as
described for all strategies above.
Cost inputs
Procedure cost estimates ranged from those derived
from Medicare fee schedules (including professional
fees and procedure reimbursement) to those reported
from a health maintenance organization.7–13, 20, 47
Based on Medicare schedules, we assumed a base case
cost of $15 for each cycle of FOBT and $22 for each
cycle of FIT.46 The PreGen Plus test list price is $495
(LabCorp; test number 512094), but the average reim-
bursement for the test is approximately $300 after
write-offs (B. Berger, personal communication; EXACT
Sciences Corporation). In the base case, we assumed a
cost of $300 for each faecal DNA test. Complication
costs were derived from relevant diagnostic-related
groups (DRG 148, major small and large bowel proce-
dures).9, 11, 20, 47, 71, 72
Stage-specific costs of care for CRC were taken
from published reports and available data on the
costs of newer therapies for advanced
CRC.5, 9, 11, 20, 31, 47, 73–75 Our Natural History model
is calibrated to SEER data on CRC stage distribution
of 39% localized, 39% regional and 22% dissemi-
nated CRC.22 After comparisons with data on CRC
TNM stage distribution, we assumed that dissemi-
nated CRC in our model represented TNM Stage IV
disease and that 2 ⁄ 3 of patients with regional CRC
in our model had TNM Stage III disease.76, 77 To
account for the increasing costs of CRC care for
advanced disease, we assumed that patients with
TNM Stage III disease received three 8-week cycles
of FOLFOX (oxaliplatin, infusional fluorouracil and
leucovorin) chemotherapy,78 resulting in an increased
cost of $34 800 over the costs assumed in our pre-
vious analyses.31 We assumed that patients with
TNM Stage IV disease received four to six cycles of
treatment including the emerging biological agents,
bevacizumab and cetuximab,28, 30, 48–51, 78, 79 result-
ing in an increased cost to $200 000.31 Base case
cost inputs incorporate these assumptions (Table 1).
Costs were updated to 2006 dollars as necessary,
using the medical services component of the consumer
price index.80 For each base case cost input, we
used the average of the published values. Indirect
costs were not included. We used a third-party payer
perspective.
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Clinical and economic outcomes
For each strategy, we determined CRC cases by stage
in a cohort of 100 000 persons, deaths by cause and
average life-years and costs per person (both dis-
counted at 3% annually).81
Cost-effectiveness of screening strategies
If one strategy afforded more life-years than another
at higher expense, an incremental cost-effectiveness
ratio was calculated. One-way sensitivity analyses
were performed on all model inputs, including test
performance characteristics and costs. Two-way sensi-
tivity analyses were performed on variables deter-
mined to be influential on one-way sensitivity
analyses. Threshold analyses were performed to iden-
tify critical values for variables at which specific con-
ditions of interest were met (e.g. clinical equivalence,
or cost-effectiveness at a willingness to pay of
$50 000–100 000 ⁄ life-year gained). A Monte Carlo
simulation with 1000 trials was performed with sam-
pling for the test performance characteristics for FOBT,
FIT and F-DNA versions 1, 1.1 and 2 from uniform
distributions representing the 95% confidence interval
ranges reported in the literature (Table 1).
In controlled trials of FOBT, adherence has been less
than perfect.32, 33, 36, 38 Initial screening rates have ran-
ged from 53% to 78%32, 33, 36, 38 and repeat screening
has ranged from 77%82 to 94%.38 Adherence is lower
outside controlled trials. Data from the Behavioral Risk
Factor Surveillance System in 2001 reported that 45%
of adults aged 50 or greater had undergone FOBT at
least once and 24% had FOBT within the past
12 months.15 Others have reported initial rates of
screening with FOBT from 35% to 47%34, 41–43, 61 and
rates of FOBT within 1 year (considered up to date) from
10% to 26%.37, 39, 40, 43, 44 Data on annual follow-up, or
serial screening, are very limited. Myers et al. reported
initial response to a screening programme of 41% (647
of 1565 subjects) and then subsequent serial screening
by 56% of initial responders (362 of 647).42 Using data
from Liang et al., adherence to annual screening can be
estimated at 61%.39 Thus, imperfect adherence was
explored in detail in sensitivity analyses.
In the base case, we assumed perfect adherence for
all strategies. This reflects the optimal possible ‘effi-
cacy’ of the strategies. The results are useful because
they reflect a strategy’s impact in persons who adhere
to it. Because imperfect adherence limits true ‘efficacy’
in larger cohorts, we performed extensive sensitivity
analyses on adherence to estimate real-world ‘effec-
tiveness’ with imperfect adherence.
RESULTS
Base case
Selection of screening interval for F-DNA. Faecal
DNA testing version 1 every 3 years compared with
every 4 years cost $39 200 ⁄ life-year gained, and every
2 years compared with every 3 years it cost
$52 600 ⁄ life-year gained (Table 2). Similarly, F-DNA
version 2 every 3 years compared with every 4 years
cost $47 700 ⁄ life-year gained, and every 2 years com-
pared with every 3 years it cost $57 100 ⁄ life-year
gained. Therefore, we selected a screening interval of
3 years for F-DNA.
Clinical outcomes with perfect adherence. Compared
with no screening, all strategies reduced CRC incidence
and mortality (Table 3). FIT yielded the greatest
number of discounted life-years ⁄ person, followed by
COLO, F-DNA version 2, FOBT, F-DNA version 1.1 and
F-DNA version 1. Without screening, a cohort of
Table 2. Effectiveness, cost and
incremental cost-effectiveness
of faecal DNA testing (F-DNA)














next shorter interval ($)
5 18.7197 3531 –
4 18.7244 3627 20 400
3 18.7305 3867 39 200
2 18.7394 4339 52 600
1 18.7478 5658 158 000
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100 000 persons experienced 5927 CRC cases, and
CRC accounted for 2.4% of deaths. Compared with no
screening, F-DNA version 1 decreased CRC incidence
by 33% and CRC-related mortality by 49%, F-DNA
version 1.1 decreased CRC incidence by 37% and CRC-
related mortality by 57%, FOBT decreased CRC
incidence by 49% and CRC-related mortality by 66%,
F-DNA version 2 decreased CRC incidence by 43% and
CRC-related mortality by 63%, COLO decreased CRC
incidence by 73% and CRC-related mortality by 80%
and FIT decreased CRC incidence by 66% and CRC-
related mortality by 78%.
Cost-effectiveness with perfect adherence. Compared
with no screening, all screening strategies increased
life-expectancy at reasonable costs (Table 3). FOBT
and FIT yielded more average life-years per person
than no screening, and achieved this at a lower
cost – i.e. they were dominant compared with no
screening. Compared with no screening, F-DNA
version 1 gained 4466 life-years ⁄ 100 000 persons at
an incremental cost of $21 200 ⁄ life-year gained,
F-DNA version 1.1 gained 5323 life-years ⁄ 100 000
persons at an incremental cost of $16 900 ⁄ life-year
gained and F-DNA version 2 gained 5795 life-
years ⁄ 100 000 persons at an incremental cost of
$15 700 ⁄ life-year gained. COLO gained 6185 life-
years ⁄ 100 000 persons at an incremental cost of
$9200 ⁄ life-year gained.
Faecal occult blood testing and FIT were preferred
over all F-DNA versions. F-DNA versions 1 and 1.1
were dominated by FOBT and FIT. F-DNA version 2
was slightly more effective than FOBT, but at a very
high incremental cost of $669 000 ⁄ life-year gained.
FIT was dominant over all other strategies, including
F-DNA version 2 (Table 3). COLO was dominated by
FIT and it cost $144 000 ⁄ life-year gained compared to
FOBT.








version 2 Colonoscopy FIT
CRC cases per 100 000 persons
from age 50 to 100 years
5927 3989 3711 3009 3403 1584 2015
CRC stage
Local 2373 2191 2231 1876 2148 882 1291
Regional 2210 1266 1086 813 943 509 504
Distant 1345 532 393 320 312 193 220
Deaths attributable to CRC 2.4% 1.2% 1.0% 0.8% 0.9% 0.5% 0.5%
Life-years ⁄ person* 18.686 18.730 18.739 18.742 18.744 18.748 18.751
Cost ⁄ person* $2921 $3867 $3821 $2683 $3833 $3489 $2428
Incremental life-years gained per 100 000 persons compared to
Natural history – 4466 5323 5623 5795 6185 6542
F-DNA version 1 – – 857 1157 1329 1719 2076
F-DNA version 1.1 – – – 300 472 862 1219
FOBT – – – – 172 562 919
F-DNA version 2 – – – – – 390 747
Colonoscopy – – – – – – 357
Increment cost per life-year gained compared to
Natural history – $21 200 $16 900 Dominates $15 700 $9200 Dominates
F-DNA version 1 – – Dominates Dominates Dominates Dominates Dominates
F-DNA version 1.1 – – – Dominates $2700 Dominates Dominates
FOBT – – – – $669 000 $144 000 Dominates
F-DNA version 2 – – – – – Dominates Dominates
Colonoscopy – – – – – – Dominates
CRC, colorectal cancer; F-DNA, faecal DNA testing every 3 years; FOBT, annual guaiac-based faecal occult blood testing; FIT,
annual faecal immunochemical testing.
* Discounted at 3% per year.
 Strategy in top row is more effective and less costly than strategy in left column to which it is being compared.
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One-way and two-way sensitivity analyses
Changes in most variables did not significantly affect
the comparisons between the F-DNA strategies and
FOBT or FIT (Table 4). If we assumed significantly
worse test performance characteristics for FOBT than
in the base case, the F-DNA strategies compared more
favourably but still cost >$50 000 ⁄ life-year gained
compared with FOBT. When we examined the low end
of reported values for FIT test performance, it was still
dominant over the F-DNA strategies. If FIT test cost
increased to $95, the strategy was no longer cost-sav-
ing compared with no screening (it cost $8300 ⁄ life-
year gained) and it cost $135 000 ⁄ life-year gained
compared with FOBT, but it was still dominant over
the F-DNA strategies. Changes in colonoscopy test per-
formance, complication rate and costs did not affect
the results significantly.
As the sensitivity for large adenoma of the F-DNA
version 2 test improved, this strategy became progres-
sively more effective than FOBT (Figure 2a). With a
sensitivity for large adenoma of 80%, F-DNA version
2 cost $87 500 ⁄ life-year gained compared with FOBT,
but this incremental cost ⁄ life-year gained rose sharply
as sensitivity for large adenoma decreased (Figure 2b).
At a test cost of $200, F-DNA version 2 cost
<$50 000 ⁄ life-year gained compared with FOBT when
F-DNA test sensitivity for large adenoma was >60%
(Figure 2b).
If we assumed lower CRC care costs because the
novel, costly therapies were not used, no screening
strategy was cost-saving anymore. Compared with no
screening, FOBT cost $8000 ⁄ life-year gained, FIT cost
$43 000 ⁄ life-year gained, F-DNA version 1 cost $33
100 ⁄ life-year gained, F-DNA version 1.1 cost $28
800 ⁄ life-year gained and F-DNA version 2 cost $27
700 ⁄ life-year gained. However, the incremental cost-
effectiveness ratios comparing the F-DNA strategies to
FOBT and FIT were not affected significantly (Table 4).
Threshold analyses on F-DNA test cost
Faecal DNA testing test cost would need to be signifi-
cantly lower than the $300 assumed in the base case
to make any of the F-DNA strategies competitive with
FOBT. F-DNA test cost would need to fall to $40 for
FOBT to cost >$50 000 ⁄ life-year gained compared to
F-DNA version 1.1. F-DNA test cost would need to fall
to $60 for F-DNA version 2 to cost <$50 000 ⁄ life-year
gained compared to FOBT.
Even when the F-DNA test was assumed to be free,
FIT cost only $9200 ⁄ life-year gained compared to
F-DNA version 1 and $8100 ⁄ life-year gained com-
pared to F-DNA version 1.1, and it still dominated
F-DNA version 2.
Monte Carlo simulation focusing on test
performance characteristics
When test performance characteristics for all stool-
based tests were varied within the ranges reported in
the literature (Table 1), FOBT was dominant over no
screening in >95% of iterations and FIT was dominant
over no screening in 100% of iterations. Compared
with no screening, the mean (and 95% confidence
interval) for the cost ⁄ life-year gained was $21 500
($16 000–29 200) for F-DNA version 1, $17 600 ($13
900–21 700) for F-DNA version 1.1 and $16 500 ($13
700–19 200) for F-DNA version 2.
Compared with F-DNA version 1.1, FOBT was domi-
nant in 88% of iterations, it cost between $100 000
and $1 000 000 ⁄ life-year gained in 18% of iterations,
and it was more costly in the remainder. Compared
with FOBT, F-DNA version 2 was dominant in 64% of
iterations, it cost <$100 000 ⁄ life-year gained in 1% of
iterations, it cost between $100 000 and
$1 000 000 ⁄ life-year gained in 28% of iterations, and
it was more costly in the remainder. Compared with
F-DNA version 2, FIT was dominant in 100% of
iterations.
Sensitivity analyses on adherence with testing
As the per-cycle (per-year) adherence with testing
decreased with FOBT and FIT, the effectiveness of
FOBT decreased steadily, and the effectiveness of FIT
began to decrease significantly when the per-cycle
adherence fell below approximately 60% (Figure 3).
Faecal DNA testing version 1.1 (with 100% adher-
ence) became more effective than FOBT when the
per-cycle adherence with FOBT fell below 85%.
F-DNA version 1.1 cost $100 000 ⁄ life-year gained
compared with FOBT when per-cycle adherence with
FOBT was 49%, and $50 000 ⁄ life-year gained
when the per-cycle adherence with FOBT was 31%
(Figure 4).
Faecal DNA testing version 2 (with 100% adherence)
became more effective than FIT when the per-cycle
adherence with FIT fell below 50%. F-DNA version 2
cost $100 000 ⁄ life-year gained compared with FIT
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when per-cycle adherence with FIT was 22%, and
$50 000 ⁄ life-year gained when the per-cycle adher-
ence with FIT was 13% (Figure 5).
Imperfect adherence with F-DNA affected the com-
parisons with FOBT and FIT. To illustrate, when the
per-cycle adherence with F-DNA version 1.1 was 50%,
F-DNA version 1.1 became more effective than FOBT
when the per-cycle adherence with FOBT fell below
35% and it cost $100 000 ⁄ life-year gained compared
with FOBT when per-cycle adherence with FOBT was
26%. Similarly, when the per-cycle adherence with F-
DNA version 2 was 50%, F-DNA version 2 became
more effective than FIT when the per-cycle adherence
with FIT fell below 19% and it cost $100 000 ⁄ life-year
gained compared with FIT when per-cycle adherence
with FIT was 12%.
DISCUSSION
Colorectal cancer screening and treatment are rapidly
evolving fields, necessitating reappraisal of the effec-
tiveness and cost-effectiveness of screening strategies
as key variables change. Our current analyses focused
on the latest test performance characteristics and costs
of non-invasive, stool-based tests, and the increasing
costs of care for advanced CRC. Our results lead to
four major conclusions. First, if CRC treatment costs
increase significantly because of the use of novel bio-
logical therapies, FOBT and FIT could improve clinical
outcomes while also achieving cost savings. Secondly,
recent improvements in test performance and lower
test cost have translated into enhanced cost-effective-
ness for F-DNA compared with no screening, but FOBT
and FIT are likely to be preferred to F-DNA when
patient adherence with yearly testing is high. Thirdly,
adherence over time is a key determinant of the effec-
tiveness of strategies that rely on frequent testing, and
F-DNA with screening every 3 years could be cost-
effective compared with FOBT and FIT in populations
with poor adherence to yearly testing. Fourthly, in
persons who can adhere to yearly testing, highly sen-
sitive and relatively inexpensive stool-based testing
such as FIT may be comparable to screening COLO.
Before the current era of novel but costly treatments
for advanced CRC, multiple analyses concluded that
CRC screening is cost-effective.3–13, 20, 22 Screening
had been estimated to be cost-saving only when very
low screening costs were assumed.83 Our current anal-
yses demonstrate how FOBT and FIT could not
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actually decrease total overall CRC-related costs
(screening, testing, complications and CRC care) if
advanced CRC is treated with novel, costly thera-
pies.28, 30, 31, 48–51, 78, 79 It is rare for medical interven-
tions to improve outcomes as well as decrease costs.
Therefore, the question is often whether an interven-
tion is ‘cost-effective’. We have previously estimated
that screening 75% of the US population with conven-
tional methods could increase overall CRC-related
costs by $1–3 billion ⁄ year, accounting for savings in
CRC care.22 However, if costly therapies for advanced
CRC become widely used, the economic benefit of pre-
vention and early detection may become large enough
that overall savings could be realized by screening.
With current test cost of $300, F-DNA version 1.1
(the currently available test PreGen Plus, LabCorp) and
F-DNA version 2 (the refined test as in Itzkowitz
et al.26) were both cost-effective compared with no
screening. Assuming the high advanced CRC care costs
associated with novel biological therapies, these strate-
gies cost approximately $17 000 ⁄ life-year gained
(upper 95% confidence interval of approximately
$22 000 ⁄ life-year gained). Without the use of novel
therapies for advanced CRC, these strategies were still
cost-effective compared with no screening
(<$30 000 ⁄ life-year gained). However, FOBT and FIT
were preferred to all F-DNA strategies when they were
not compromised by poor adherence.
With current test performance characteristics and
good adherence, substantial decreases in test cost
would be required for any F-DNA test to become cost-
effective compared with FOBT. F-DNA test cost would
need to be $40–60 for F-DNA versions 1.1 and 2 to
compare favourably with FOBT at a threshold of
$50 000 ⁄ life-year gained. More dramatically, FIT dom-











0 10 20 30 40 50 60 70 80 


























0 10 20 30 40 50 60 70 80 














F-DNA version 2 
at $300 vs. FOBT 
F-DNA version 2 
at $200 vs. FOBT 
F-DNA version 2 
at $300 vs. Natural 
History 
(a) (b) 
Figure 2. (a) Impact of sensitivity for large adenoma on the effectiveness of faecal DNA testing (F-DNA). The effectiveness
of F-DNA increases as sensitivity for large adenoma improves. (b) Impact of sensitivity for large adenoma and test cost on
the cost-effectiveness of F-DNA. At a test cost of $200 and test sensitivity for large adenoma of >60%, F-DNA version 2











0 10 20 30 40 50 60 70 80 90 100

















Figure 3. Impact of adherence on the effectiveness of
faecal occult blood testing (FOBT) and faecal immuno-
chemical testing (FIT). As adherence with yearly testing
decreased, the effectiveness of FOBT decreased steadily,
and the effectiveness of FIT decreased significantly with
per-cycle adherence below 60%.
REAPPRAIS ING STOOL-BASED COLORECTAL NEOPLAS IA SCREENING 707
ª 2008 The Authors, Aliment Pharmacol Ther 27, 697–712
Journal compilation ª 2008 Blackwell Publishing Ltd
and it was preferred even when the F-DNA test was
assumed to be free.
Early detection of CRC, as well as CRC prevention
through removal of adenomas, underlies the benefit of
screening. In the base case, we assumed low F-DNA
sensitivity for large adenoma. Better sensitivity for
large adenoma would improve F-DNA’s effectiveness
(Figure 2a), but the effect appears less dramatic than
we expected initially. This result depends on the
assumption that most CRCs remain localized or regio-
nal for several years, and can therefore be detected at
a high rate with a relatively sensitive test that is per-
formed every 3 years. Similarly, for adenomas that
‘dwell’ for many years, repeated testing with only a
fair test has a reasonably high cumulative sensitivity.
The predictions of our model as regards the effective-
ness of FOBTs are very close to the results of clinical
trials,22, 32, 33 giving us confidence as regards our pre-
dictions for F-DNA. However, if the fraction of rapidly
advancing adenomas or tumours is higher than
reflected in our current model, the benefit of improved
sensitivity for large adenoma may be underestimated.
Not surprisingly, we found that adherence over time
is a key determinant of the effectiveness of strategies
that rely on frequent testing (Figure 3). Even in the
idealized setting of a controlled trial, adherence to
annual or biannual FOBT is less than ideal.32, 33, 36, 38
In clinical practice, it has been difficult to achieve
ongoing high rates of adherence with FOBT,39, 42 and
the follow-up of abnormal tests is difficult to
ensure.32, 33, 36, 38, 41, 61 Furthermore, patient prefer-
ences for screening options vary.16, 84–90 Because
changing the adherence rates of multiple strategies
simultaneously is cumbersome, we compared F-DNA
with perfect adherence against FOBT and FIT
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Figure 4. Impact of adherence
on the effectiveness and cost-
effectiveness of faecal DNA
testing (F-DNA) version 1.1
compared with faecal occult
blood testing (FOBT). F-DNA
version 1.1 became more
effective than FOBT when the
per-cycle adherence with FOBT
fell below 85%, and it cost an
incremental $50 000 ⁄ life-year
gained when the per-cycle
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Figure 5. Impact of adherence
on the effectiveness and cost-
effectiveness of faecal DNA
testing (F-DNA) version 2
compared with faecal immu-
nochemical testing (FIT). F-
DNA version 2 became more
effective than FIT when the
per-cycle adherence with FIT
fell below 50%, and it cost an
incremental $100 000 ⁄ life-
year gained when per-cycle
adherence with FIT was 22%.
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conceivable that F-DNA could be considered cost-
effective compared with FOBT or FIT in populations
that demonstrate good to excellent adherence with
testing every 3 years, but which would otherwise have
very poor adherence with yearly testing. Further study
is required in this area.
In persons adhering perfectly with screening, which
reflects optimal efficacy, screening COLO decreased
CRC incidence more than annual FIT, but the average
life-expectancy with FIT was higher than with screen-
ing colonoscopy. This is explained by the fact that
most CRCs were diagnosed at treatable stages. The
generalizable conclusion is that among persons who
can comply with frequent testing, highly sensitive and
inexpensive non-invasive testing may be comparable
to much less frequent screening with colonoscopy.
The current reappraisal raises important points when
compared with our first analysis of F-DNA.20 As F-
DNA’s test performance has improved and its cost has
decreased, it has become more cost-effective when
compared with no screening, an effect that is accentu-
ated as the cost of CRC care increases. However, colo-
noscopy remains preferred over F-DNA with current
parameters. In our first analysis, we did not focus on
the comparison between stool-based tests, which is the
principal subject of our current reappraisal. Our cur-
rent results highlight that, in the setting of good
adherence, FOBT and FIT are likely to be preferred to
F-DNA.
Our analysis has some limitations. Indirect costs
were not included. Patterns of adherence over time are
likely to be complex, and such considerations are
beyond the scope of the current analyses. Finally, as
in all decision analyses, there is uncertainty surround-
ing important inputs. However, we have addressed the
key variables in extensive sensitivity analyses to be
able to draw conclusions that may focus future clinical
research and inform policy decisions.
In conclusion, our analyses suggest that as the costs
of care for advanced CRC increase because of use of
novel but costly biological therapies, screening with
reasonably effective and inexpensive methods such as
FOBT and FIT can be not only cost-effective, but also
potentially cost-saving. The evolution of test perfor-
mance characteristics and decrease in test cost for
F-DNA have translated into improved cost-effective-
ness for F-DNA compared with no screening, but pres-
ently FOBT and FIT remain preferred to F-DNA in
populations with high adherence to yearly testing.
F-DNA with excellent adherence can be considered
cost-effective compared with FOBT or FIT in popula-
tions with very poor adherence to yearly testing. With
excellent annual adherence, sensitive and inexpensive
stool-based testing such as FIT may be comparable to
screening colonoscopy.
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